Does Monoamine Oxidase Inhibitors Maois Interact with Pramlintide Acetate?
CDI records a moderate classification for Monoamine Oxidase Inhibitors Maois and Pramlintide Acetate. The stored summary is: May increase susceptibility to hypoglycemia when coadministered with SYMLIN. Use with caution. The mechanism involves increased hypoglycemia risk. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Increased hypoglycemia risk
What To Tell Your Doctor or Pharmacist
If you are taking Monoamine Oxidase Inhibitors Maois and your doctor is considering prescribing Pramlintide Acetate (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider